NCT02374489: A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma |
|
|
| Terminated | 2 | 9 | RoW | LDK378, ceritinib(Zykadia) | National Health Research Institutes, Taiwan, National Cheng-Kung University Hospital, National Taiwan University Hospital | Cholangiocarcinoma | 01/18 | 01/18 | | |
NCT02638909: Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies |
|
|
| Terminated | 2 | 4 | US | ceritinib, Zykadia | Criterium, Inc., University of Colorado, Denver, Novartis | Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma | 03/18 | 03/18 | | |
